March is National Colorectal Cancer Awareness Month. The 5-year survival rate for a colorectal cancer patient when detected at an early stage is 90%, which drastically plummets down to 14% if cancer gets spread to a distant part of the body. Only 39% of patients are diagnosed at an early stage of colorectal cancer.
This National Colorectal Cancer Awareness Month, BioGenex is focusing on early detection and accurate diagnosis using a wide panel of antibodies.
Early and accurate diagnosis using immunohistochemistry improves the outcome of the patient's treatment around the world. This can be accomplished using a specific panel of antibodies that are validated on human tissues. BioGenex offers several antibody panels for various cancer diagnosis.
IHC Antibody panel for Colorectal Cancer
CA19.9, MUC2, p53, EGFR, CDX2, CEA, CK20, CK7, CK5, CD117, DOG1, VEGF, Beta-Catenin, MLH1, MSH2, MSH6, PMS2, Her2, Pan CK, CK19, Epcam, Survivin, CEA
BioGenex offers over 400 antibodies for various panels in ready-to-use and concentrated format. Our antibodies are compatible with fully automated staining systems and detection systems for clean and intense staining.